Press releases arkiv | Affibody Medical AB

Affibody Medical Investor Relations

Categories:

Navigation:

Regulatory

March 27, 2026

Izokibep Demonstrates Durable Efficacy in Phase 3 Study in Hidradenitis Suppurativa as Presented at AAD 2026

Stockholm, Sweden, March 27, 2026. Affibody AB (“Affibody”) today announced positive 32-week data from a global Phase 3 study of the next generation IL-17A inhibitor izokibep in hidradenitis suppurativa...

Regulatory

February 19, 2026

Affibody Signs Letter of Intent with SHINE Technologies for Supply of Lutetium-177

Stockholm, Sweden, February 19, 2026. Affibody AB (“Affibody”) today announced that a Letter of Intent (LOI) has been signed with SHINE Technologies, LCC (“SHINE”) as an additional supplier of...

Regulatory

February 17, 2026

Affibody’s licensee Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement

Stockholm, Sweden, February 17, 2026. Affibody’s licensee Rallybio Corporation (Rallybio) has today announced positive results from its Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) clinical study evaluating RLYB116, an innovative, once-weekly,...

News

February 12, 2026

Affibody Medical announces outcome of rights issue

Stockholm, Sweden, February 12, 2026. Affibody Medical AB (publ) (”Affibody” or the “Company”) today announced the outcome of the Company’s rights issue of approximately SEK 307 million (the “Rights...

News

February 5, 2026

Report from Extraordinary General Meeting in Affibody Medical AB (publ)

Stockholm, Sweden, February 5, 2026. Affibody Medical AB (publ) today held an Extraordinary General Meeting. The following resolutions were adopted. The General Meeting resolved on the introduction of an...

Regulatory

January 20, 2026

Affibody Carries Out Fully Guaranteed Rights Issue of SEK 307 Million

Stockholm, Sweden, January 20, 2026. Affibody Medical AB (publ) (“Affibody”) today announced that the Board of Directors, with authorization from the annual general meeting on May 27, 2025, has...

News

January 19, 2026

NOTICE OF EXTRAORDINARY GENERAL MEETING IN AFFIBODY MEDICAL AB (PUBL)

The shareholders of Affibody Medical AB (publ), corporate identity number 556714-5601 (the “Company” or “Affibody”) are hereby invited to attend an extraordinary general meeting of the shareholders on Thursday...

Regulatory

December 16, 2025

Affibody Accelerates Phase 1 Study with ABY-271 Following Initial Patient Data

Stockholm, Sweden, December 16, 2025. Affibody AB (“Affibody”) today announced that the Trial Review Committee (TRC) has recommended to advance the Phase I clinical study with the Radioligand Therapy...

News

November 26, 2025

Affibody’s Nomination Committee for the 2026 Annual General Meeting

Stockholm, Sweden, November 26, 2025. Affibody Medical AB (publ) today announced the composition of the Nomination Committee for the 2026 Annual General Meeting (AGM) to be held on May...